SAN JOSE, Calif.--(BUSINESS WIRE)--Colby Pharmaceutical Company (Colby), a private San Jose, CA biopharmaceutical company, announced that it received a National Cancer Institute (NCI) SBIR funding award for small molecule inhibitors of interactions between Androgen Receptor (AR) Protein with JunD Oncoprotein for treatment of prostate cancer (PCa).
